Carfilzomib-based studies: comparison of grade >3 treatment emergent adverse event (TEAE) and cardiac events by age and fitness49
| . | ASPIRE50 . | ENDEAVOR51 . | ARROW52 . | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade ≥3 TEAE, n (%) | <70 | KRd | 236 (81.7) | Fit | KRd | 102 (89) | <65 | Kd | 152 (68.2) | Fit | Kd | 91 (83) | <65 | 1 × Kd | 61 (59.2) | Fit | 1 × Kd | 33 (55) |
| Rd | 215 (77.6) | Rd | 96 (84) | Vd | 131 (63) | Vd | 76 (64) | 2 × Kd | 58 (56.3) | 2 × Kd | 41 (62) | |||||||
| ≥70 | KRd | 92 (89.3) | Frail | KRd | 86 (93) | 65-74 | Kd | 124 (76.1) | Frail | Kd | 142 (85) | 65-74 | 1 × Kd | 62 (68.9) | Frail | 1 × Kd | 64 (81) | |
| Rd | 99 (88.4) | Rd | 94 (94) | Vd | 128 (69.9) | Vd | 125 (79) | 2 × Kd | 64 (63.4) | 2 × Kd | 42 (70) | |||||||
| ≥75 | Kd | 63 (81.8) | ≥75 | 1 × Kd | 38 (84.4) | |||||||||||||
| Vd | 46 (70.8) | 2 × Kd | 23 (74.2) | |||||||||||||||
| Grade ≥3 cardiac failure, n (%) | <70 | KRd | 6 (2.1) | Fit | KRd | 5 (4) | <65 | Kd | 6 (2.7) | Fit | Kd | 4 (4) | <65 | 1 × Kd | 1 (1) | Fit | 1 × Kd | 1 (2) |
| Rd | 5 (1.8) | Rd | 2 (2) | Vd | 3 (1.4) | Vd | 2 (2) | 2 × Kd | 6 (5.8) | 2 × Kd | 1 (2) | |||||||
| ≥70 | KRd | 9 (8.7) | Frail | KRd | 9 (10) | 65-74 | Kd | 8 (4.9) | Frail | Kd | 15 (9) | 65-74 | 1 × Kd | 5 (5.6) | Frail | 1 × Kd | 3 (4) | |
| Rd | 2 (1.8) | Rd | 1 (1) | Vd | 3 (1.6) | Vd | 7 (4) | 2 × Kd | 2 (2) | 2 × Kd | 5 (8) | |||||||
| ≥75 | Kd | 8 (10.4) | ≥75 | 1 × Kd | 1 (2.2) | |||||||||||||
| Vd | 2 (3.1) | 2 × Kd | 2 (6.5) | |||||||||||||||
| Grade ≥3 ischemic heart disease, n (%) | <70 | KRd | 8 (2.8) | Fit | KRd | 4 (3) | <65 | Not given | Fit | Kd | 2 (2) | <65 | 1 × Kd | 1 (1) | Fit | 1 × Kd | 1 (1) | |
| Rd | 7 (2.5) | Rd | 3 (3) | Vd | 2 (<1) | 2 × Kd | 0 | 2 × Kd | 0 | |||||||||
| ≥70 | KRd | 5 (4.9) | Frail | KRd | 7 (8) | 65-74 | Frail | Kd | 8 (5) | 65-74 | 1 × Kd | 0 | Frail | 1 × Kd | 0 | |||
| Rd | 1 (0.9) | Rd | 1 (1) | Vd | 6 (4) | 2 × Kd | 1 (1) | 2 × Kd | 1 (2) | |||||||||
| ≥75 | ≥75 | 1 × Kd | 1 (2.2) | |||||||||||||||
| 2 × Kd | 1 (3.2) | |||||||||||||||||
| . | ASPIRE50 . | ENDEAVOR51 . | ARROW52 . | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade ≥3 TEAE, n (%) | <70 | KRd | 236 (81.7) | Fit | KRd | 102 (89) | <65 | Kd | 152 (68.2) | Fit | Kd | 91 (83) | <65 | 1 × Kd | 61 (59.2) | Fit | 1 × Kd | 33 (55) |
| Rd | 215 (77.6) | Rd | 96 (84) | Vd | 131 (63) | Vd | 76 (64) | 2 × Kd | 58 (56.3) | 2 × Kd | 41 (62) | |||||||
| ≥70 | KRd | 92 (89.3) | Frail | KRd | 86 (93) | 65-74 | Kd | 124 (76.1) | Frail | Kd | 142 (85) | 65-74 | 1 × Kd | 62 (68.9) | Frail | 1 × Kd | 64 (81) | |
| Rd | 99 (88.4) | Rd | 94 (94) | Vd | 128 (69.9) | Vd | 125 (79) | 2 × Kd | 64 (63.4) | 2 × Kd | 42 (70) | |||||||
| ≥75 | Kd | 63 (81.8) | ≥75 | 1 × Kd | 38 (84.4) | |||||||||||||
| Vd | 46 (70.8) | 2 × Kd | 23 (74.2) | |||||||||||||||
| Grade ≥3 cardiac failure, n (%) | <70 | KRd | 6 (2.1) | Fit | KRd | 5 (4) | <65 | Kd | 6 (2.7) | Fit | Kd | 4 (4) | <65 | 1 × Kd | 1 (1) | Fit | 1 × Kd | 1 (2) |
| Rd | 5 (1.8) | Rd | 2 (2) | Vd | 3 (1.4) | Vd | 2 (2) | 2 × Kd | 6 (5.8) | 2 × Kd | 1 (2) | |||||||
| ≥70 | KRd | 9 (8.7) | Frail | KRd | 9 (10) | 65-74 | Kd | 8 (4.9) | Frail | Kd | 15 (9) | 65-74 | 1 × Kd | 5 (5.6) | Frail | 1 × Kd | 3 (4) | |
| Rd | 2 (1.8) | Rd | 1 (1) | Vd | 3 (1.6) | Vd | 7 (4) | 2 × Kd | 2 (2) | 2 × Kd | 5 (8) | |||||||
| ≥75 | Kd | 8 (10.4) | ≥75 | 1 × Kd | 1 (2.2) | |||||||||||||
| Vd | 2 (3.1) | 2 × Kd | 2 (6.5) | |||||||||||||||
| Grade ≥3 ischemic heart disease, n (%) | <70 | KRd | 8 (2.8) | Fit | KRd | 4 (3) | <65 | Not given | Fit | Kd | 2 (2) | <65 | 1 × Kd | 1 (1) | Fit | 1 × Kd | 1 (1) | |
| Rd | 7 (2.5) | Rd | 3 (3) | Vd | 2 (<1) | 2 × Kd | 0 | 2 × Kd | 0 | |||||||||
| ≥70 | KRd | 5 (4.9) | Frail | KRd | 7 (8) | 65-74 | Frail | Kd | 8 (5) | 65-74 | 1 × Kd | 0 | Frail | 1 × Kd | 0 | |||
| Rd | 1 (0.9) | Rd | 1 (1) | Vd | 6 (4) | 2 × Kd | 1 (1) | 2 × Kd | 1 (2) | |||||||||
| ≥75 | ≥75 | 1 × Kd | 1 (2.2) | |||||||||||||||
| 2 × Kd | 1 (3.2) | |||||||||||||||||
Frailty assessment based on the IMWG frailty index.6,54